<DOC>
	<DOCNO>NCT00948428</DOCNO>
	<brief_summary>At end study , safety efficacy outcome measure compare determine ) dose Generic Imiquimod cream , 5 % therapeutically equivalent currently market Aldara ( imiquimod ) cream , 5 % b ) imiquimod 5 % creams superior comparison Vehicle cream .</brief_summary>
	<brief_title>Bioequivalence Generic Imiquimod Cream , 5 % When Compared Aldara™ ( Imiquimod ) Cream , 5 % Treatment Actinic Keratosis</brief_title>
	<detailed_description>A nationwide , multicenter , double-blind , vehicle-controlled parallel group comparison study Generic Imiquimod cream , 5 % ( Actavis Mid-Atlantic LLC ) currently market Aldara ( imiquimod ) cream , 5 % ( distribute Graceway Pharmaceuticals , LLC ) conduct subject actinic keratoses ( AKs ) face and/or anterior scalp order evaluate therapeutic equivalence two active treatment establish superiority efficacy two product Vehicle cream . Subjects randomize one three treatment group 2:2:1 basis follow : ( 1 ) Generic Imiquimod cream , 5 % , ( 2 ) Aldara ( imiquimod ) cream , 5 % , ( 3 ) Vehicle cream . The duration treatment 16 week ( ± 7 day ) . The primary efficacy endpoint proportion subject treatment group Complete Clearance ( clinically visible actinic keratosis lesion 25 cm2 contiguous treatment area 8-week post-treatment visit ) AK lesion . The secondary efficacy endpoint Partial Clearance rate , define proportion subject least 75 % reduction number AK lesion count Baseline end-of-treatment visit ( Week 16 , EOT ) 8 week post-treatment visit/test-of-cure ( Week 24 , TOC ) , proportion subject Complete Clearance AK lesion end-of-treatment ( Week 16 , EOT ) visit . A 90 % Wald 's confidence interval Yate 's continuity correction construct around difference proportion subject Complete Clearance AK lesion active treatment ( Generic Imiquimod minus Aldara ) evaluate therapeutic equivalence primary efficacy analysis . Two-sided , continuity-corrected statistic use evaluate superiority active treatment 's Complete Clearance rate Vehicle treatment . The therapeutic comparability evaluation per-protocol ( PP ) population consider primary intent-to-treat ( ITT ) population consider supportive . The superiority comparison ITT population consider primary PP population consider supportive . If 90 % confidence interval ( CI ) around difference Generic Imiquimod Aldara Complete Clearance rate PP population contain within interval 0.20 +0.20 , rate great , statistically different ( p &lt; 0.05 ) , Vehicle rate ITT population , Generic Imiquimod Aldara consider therapeutically equivalent . Secondary efficacy analysis conduct proportion subject treatment group Complete Clearance AK lesion Week 16 , EOT visit well evaluation Partial Clearance AK lesion EOT TOC visit . The result EOT visit ( Week 16 ) 8 week post-treatment ( Week 24 , TOC ) statistically analyze method describe primary efficacy variable . Both EOT TOC analyse conduct ITT population . The TOC analysis conduct PP population EOT analysis conduct EOT PP population .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Subjects male nonpregnant female , 18 year age older , generally good health . Females postmenopausal , surgically sterile use medically acceptable form birth control negative urine pregnancy test Baseline visit . Subjects provide write verbal informed consent . Subjects present clinic least 4 12 visible , discrete nonhyperkeratotic , nonhypertrophic actinic keratosis lesion within 25 cm2 Treatment Area face and/or anterior scalp . Subjects willing able comply study instruction return clinic require visit . Subjects lactate , plan become pregnant study . Subjects hyperkeratotic , hypertrophic large matlike AKs within 25 cm2 Treatment Area . Subjects need plan expose artificial tanning device excessive sunlight trial . Subjects immunosuppressed ( e.g. , HIV , systemic malignancy , graft vs. host disease , etc. ) . Subjects experience unsuccessful outcome previous imiquimod therapy . Subjects know hypersensitivity previous allergic reaction active inactive component study drug . Within 2 month : Facial and/or Anterior Scalp : laser resurfacing , photodynamic therapy , chemical peel , dermabrasion , topical application 5FU , imiquimod , diclofenac sodium treatment AK photodamage . Subjects use follow systemic , oral topical therapy period specify prior entry study : Within 2 day : Topicals kind select Treatment Area . Within 2 week : Facial topical medication : corticosteroid , alpha hydroxyacids ( e.g. , glycolic acid , lactic acid , etc . great 5 % ) , betahydroxyacid ( salicylic acid great 2 % ) , urea great 5 % prescription retinoids ( e.g. , tazarotene , adapalene , tretinoin ) face and/or anterior scalp . Within 2 week : Cryotherapy lesion adjacent within 25 cm2 Treatment Area . Within 4 week : Systemic steroid therapy : chemotherapeutic agent , psoralens , immunotherapy , retinoids .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>actinic keratoses</keyword>
	<keyword>imiquimod</keyword>
	<keyword>therapeutic equivalence</keyword>
	<keyword>bioequivalence</keyword>
</DOC>